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Introduction {#sec1}
============

Mucosal antibodies are essential in maintaining host-microbial homeostasis and protecting from invading pathogens ([@bib29], [@bib38], [@bib69]). Early during HIV-1 infection, massive depletion of gut CD4^+^ T cells, notably follicular T helper cells (TFH), and loss of germinal centers in mucosa-associated lymphoid tissues impair the induction of antibody responses ([@bib12], [@bib30], [@bib41]). Bacterial translocation and subsequent immune activation and/or inflammation in the mucosa of infected individuals may also weaken local humoral immunity ([@bib16], [@bib27], [@bib54]). Nonetheless, early antiretroviral therapy (eART) partially prevents HIV-1-induced mucosal damages and immune dysregulation ([@bib15], [@bib28], [@bib54]). eART allows preserving functional gut TFH and resting memory B cells specific to glycoprotein (gp)140 trimers ([@bib53]). Mucosal transmission of HIV-1 induces a local production of immunoglobulin (Ig)G and IgA antibodies that predominantly target the gp41 subunit of the viral envelope glycoprotein gp160 ([@bib72], [@bib79]). However, whether they limit viral dissemination upon HIV-1 exposure is unclear ([@bib2], [@bib13], [@bib73]). Polyreactive antibodies naturally produced by intestinal B cells and coating commensals *in situ* have been proposed to compromise optimal humoral responses to HIV-1 by immune diversion ([@bib9]). However, overall, very little is known about the antibody response to HIV-1 at mucosal sites and the properties of gut-resident B cells recognizing the virus.

Single-cell, antigen-specific capture and expression cloning of human antibodies greatly facilitated decoding systemic memory B cell responses to gp140 in HIV-1-infected individuals ([@bib44]). This also allowed the discovery of broadly neutralizing antibodies with *in vivo* prophylactic and therapeutic efficacy ([@bib14]). However, the humoral response to HIV-1 in mucosal tissues was never, to our knowledge, investigated with antigen-baiting strategies for characterizing gp140-reactive B cell antibodies. Here, we interrogated the intestinal B cell response to HIV-1 by characterizing 76 recombinant monoclonal antibodies from gp140-binding IgA^+^ and IgG^+^ B cells from rectosigmoid colon tissues of HIV-1-infected individuals. We show that most mucosal B cell antibodies are polyreactive, displaying only a low affinity to gp160. High-affinity, intestinal HIV-1 antibodies were also identified but lacked antibody-dependent cellular cytotoxicity (ADCC) potency against transmitted founder (T/F) viruses, did not neutralize HIV-1 or block its transcytosis across mucosal epithelium, and cross-reacted with self-antigens. This suggests an inability of the gut immune system to locally generate functional high-affinity antibodies in response to HIV-1 infection.

Results {#sec2}
=======

Capture of HIV-1-Reactive Intestinal B Cells from Infected Individuals {#sec2.1}
----------------------------------------------------------------------

To characterize HIV-1-reactive B cells residing in tertiary lymphoid structures of the intestinal mucosa, we obtained colorectal biopsies from five HIV-1^+^ individuals, four of them being infected with clade-B viruses ([Table S1](#mmc2){ref-type="supplementary-material"}). All donors had serum IgG antibodies to trimeric gp140, gp120, and gp41 proteins with no detectable *in vitro*, neutralizing activity ([Figures 1](#fig1){ref-type="fig"}A and 1B). As expected, blood class-switched (CS) B cells were mostly IgG^+^ (16.6% versus 5.3% for IgA^+^), whereas CS memory B cells and plasmablasts in the intraepithelial lymphocyte (IEL) and lamina propria lymphocyte (LPL) compartments expressed predominantly surface IgAs (14.6% and 17% versus 9.3% and 13.4% for IgG^+^ cells, respectively) ([Figures 1](#fig1){ref-type="fig"}C, [S1](#mmc1){ref-type="supplementary-material"}A, and S1C). Flow-cytometric immunophenotyping showed equal proportions of mature naive (MN) and resting memory (RM) B cells in the IEL compartment (36.5% versus 41.3%) but about twice more RM than MN B cells in the LPL (48.6% versus 25.4%) ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}B). Mucosal IgA^+^ and IgG^+^ B cells were stained with fluorescently labeled, clade-B, YU-2 gp140 trimers ([Figures 1](#fig1){ref-type="fig"}E, [S1](#mmc1){ref-type="supplementary-material"}D, and S1E). The vast majority of gp140-reactive mucosal B cells expressed surface IgA and mainly originated from the *lamina propria* for the non-treated (NT) and late-treated ART (lART) patients and from the IEL compartment for the early treated (eART) patient ([Figure 1](#fig1){ref-type="fig"}F). Immunoglobulin gene analyses showed that apart from an enrichment of V~H~1 gene usage in gp140-captured mucosal B cells, which mostly originated from lART-derived cells (27%; particularly V~H~1--18 and V~H~1--46 genes), no major variations were observed when compared with healthy blood and mucosal, global, B cell repertoires ([@bib3], [@bib55]) ([Figure S2](#mmc1){ref-type="supplementary-material"}; [Table S2](#mmc3){ref-type="supplementary-material"}). These B cells displayed relatively high levels of somatic mutations in IgH and IgL variable gene segments, with more mutated antibodies isolated from lART donors ([Figure S2](#mmc1){ref-type="supplementary-material"}F; [Table S2](#mmc3){ref-type="supplementary-material"}).Figure 1Capture of HIV-1 Env-Reactive Mucosal B Cells(A) Representative ELISA graph showing the reactivity of purified serum IgG (sIgG) from HIV-1-infected individuals (n = 5) against trimeric gp140, gp120, and gp41 proteins. Error bars indicate the SEM of duplicate values. Ctr^+^, positive control sIgG; pt3, patient 3 ([@bib65]); Ctr^−^, negative control sIgG; hd2, healthy donor 2 ([@bib55]).(B) Neutralization activity of sIgG from HIV-1-infected donors (n = 5) measured by TZM-bl assay.(C) Dot plots comparing the percentage of IgA^+^CD19^+^ and IgG^+^CD19^+^ cells in the IEL, LPL, and peripheral blood mononuclear cell (PBMC) compartments determined by flow cytometry as shown in [Figure S1](#mmc1){ref-type="supplementary-material"}. Median values are indicated below.(D) Dot plots comparing the distribution of B cell subsets in the IEL, LPL, and PBMC compartments determined by flow cytometry as shown in [Figure S1](#mmc1){ref-type="supplementary-material"}. Percentage of mature naive (MN), resting memory (RM), activated memory (AM), and tissue-like memory (TLM) B cells and antibody-secreting cells (ASC) are shown.(E) HIV-1 gp140-reactive B cell fluorescence-activated cell sorting (FACS). (Top) Cytograms show the gating strategy used for single-cell sorts of gp140-binding mucosal B cells. An example is given for patient COA21. (Bottom) Dot plots comparing the percentage of gp140-reactive IgA^+^ and IgG^+^ CD19^+^ lymphocytes from the IEL, LPL, and PBMC compartments determined by flow cytometry as shown in [Figure S1](#mmc1){ref-type="supplementary-material"}.(F) Pie charts show the distribution of single gp140-binding B cells captured by FACS with YU-2 gp140 trimers among IEL and LPL IgA^+^ and IgG^+^ B cell populations. The number of B cells captured is indicated in the center of each pie chart.(G) Representative ELISA graph showing the reactivity of gp140-captured mucosal monoclonal antibodies (mAbs; n = 76) against YU-2 gp140 trimers. Error bars indicate the SEM of duplicate values. Dotted black and green lines represent the positive control 10-1074 and negative control mGO53 IgG antibodies, respectively. The proportion of high affinity anti-gp140 antibodies in each patients' group is shown below in the pie charts. The total number of tested antibodies is indicated in the center of each pie chart.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

Mucosal Non-neutralizing HIV-1 Antibodies Lack Potent ADCC Activity against T/F Viruses {#sec2.2}
---------------------------------------------------------------------------------------

Only 4 of the 76 antibodies produced bound to YU-2 gp140 trimers with high affinity ([Figure 1](#fig1){ref-type="fig"}G; [Table S2](#mmc3){ref-type="supplementary-material"}). Three of them were specific for the gp41 subunit ([Figure 2](#fig2){ref-type="fig"}A); 6-159 bound to the putative immunodominant peptide (PID), whereas 6-195 and 64-i109 reacted against conformational gp41 epitopes ([Figure 2](#fig2){ref-type="fig"}B). ELISA binding analyses on gp120 mutant proteins indicated that 6-104 targets the CD4-induced site (CD4i) ([Figure 2](#fig2){ref-type="fig"}B). None of the mucosal HIV-1 antibodies, either expressed as IgG or IgA (as found *in situ* for 6-159 and 6-195), had measurable *in vitro* neutralizing activity against a five-virus panel ([Figure 2](#fig2){ref-type="fig"}C). Non-neutralizing HIV-1 antibodies (nnAbs) can exert ADCC activity against HIV-1-infected target cells ([@bib7], [@bib23], [@bib59]). Because the killing process requires opsonization of target cells, we first examined the binding of mucosal HIV-1 antibodies to CD4^+^ T cells infected with three laboratory-adapted and six T/F viruses. In agreement with our previous work ([@bib7]), nnAbs bound well to cells infected with laboratory-adapted strains but only poorly to T/F-infected cells ([Figures 2](#fig2){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}). As previously reported for prototypical anti-PID 5-25 ([@bib7]), the strongest binding was observed with 6-159, which stained most cells infected with laboratory-adapted viral strains (81%--86%), but only 0.5%--17% of those harboring T/F virions ([Figures 2](#fig2){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}). Consistent with binding data, 6-159 and, to a lesser extent, the other mucosal HIV-1 nnAbs induced ADCC-mediated killing of targets cells infected by laboratory-adapted strain NL4.3 (64% and 29%--35%, respectively) ([Figure 2](#fig2){ref-type="fig"}E). However, mucosal IgGs displayed weak ADCC activities against CH058 and CH077 T/F viruses compared with 3BNC117 and PGT128 broadly neutralizing antibodies (bNAbs) ([Figure 2](#fig2){ref-type="fig"}E). Mucosal nnAbs did not block HIV-1 transcytosis across epithelial cell monolayers ([Figure 2](#fig2){ref-type="fig"}F) and, in contrast to bNAbs ([@bib37]), they did not neutralize transcytosed virions ([Figure 2](#fig2){ref-type="fig"}G). All gp41 nnAbs showed interactions with colon-prominent mucin 2, but only 6-159 was able to capture free T/F virions ([Figures 2](#fig2){ref-type="fig"}H and 2I), suggesting that mucosal anti-PID antibodies could have the ability to trap incoming HIV-1 viruses into mucosa-associated mucin networks.Figure 2Epitopes and Antiviral Activities of Mucosal HIV-1 gp140 Antibodies(A) Representative ELISA graphs show the binding of mucosal HIV-1-specific antibodies to trimeric gp140, gp120 and gp41 proteins. Error bars indicate the SEM of quadruplicate values. The green dotted line corresponds to the negative control antibody mGO53.(B) Epitope mapping. (Left) Representative ELISA graph comparing the binding of anti-gp120 antibody 6-104 to wild-type gp120, gp120^core^, gp120^D368R^, and gp^I420R^ mutant proteins. Error bars indicate the SEM of quadruplicate values. (Right) Representative ELISA graph shows the reactivity of mucosal anti-gp41 monoclonal antibodies (mAbs) against overlapping peptides covering the extracellular portion of gp41 (gp41^EC^). The sequence of the peptide recognized by 6-159 is indicated on the top.(C) Plot shows the neutralization activity of mucosal gp140-specific mAbs as measured in duplicate in two independent *in vitro* TZM-bl assay experiments (one representative is shown).(D) Antibody binding to infected target cells. (Left) Graph shows the binding of anti-gp140 IgGs to NL4.3-infected cells, measured as the percentage of IgG^+^ in Gag^+^ cells by flow cytometry. (Right) Heat map comparing the percentage of bound, infected cells (n = 9 viruses) by antibodies (at 15 μg/ml) assayed by flow cytometry as shown in [Figure S3](#mmc1){ref-type="supplementary-material"}. 3BNC117 and mGO53 are positive and negative control, respectively.(E) Bar graphs comparing the ADCC activity of HIV-1 nnAbs and bNAbs (PGT128 and 3BNC117) against target cells infected by selected viruses as measured by flow cytometry. Mean values (dots) ± SEM of three independent experiments performed in duplicate are shown. mGO53 is the non-HIV-1 isotype control.(F) Bar graph shows the percentage of transcytosis of NLAD8 alone (white, no antibody), in the presence of non-HIV-1 mGO53 control (gray), HIV-1 bNAb 10-1074, and mucosal HIV-1 antibodies expressed as monomeric IgG (blue) and IgA (orange) antibodies. Mean values ± SEM of quadruplicate values from two independent experiments (dots) are shown.(G) Scatter plot shows the infectivity level of transcytosed NLAD8 viruses derived from the experiments shown in (F) on TZM-bl reporter cells. Antibodies were tested at a final concentration of 66.7 nM. RLU, relative light units. Groups in (F) and (G) were compared to the no-antibody control by the Mann-Whitney test. ns, not significant; ^∗∗∗^p \< 0.001.(H) Bar graphs show the amount of free viruses captured by mucosal HIV-1 and control antibodies measured by ELISA as p24 content. Mean of quadruplicate values ± SEM are shown.(I) ELISA graphs show the binding of mucosal HIV-1 and control antibodies to purified human mucin 2. Mean values ± SEM of two independent experiments performed in duplicate are shown.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Polyreactive Blood and Mucosal B Cell Antibodies from Non-Infected Humans Recognize HIV-1 Envelope Glycoproteins {#sec2.3}
----------------------------------------------------------------------------------------------------------------

Only a small fraction of the captured B cell antibodies recognized gp140 trimers with high affinity. We thus wondered whether the 72 remaining ones were enriched for polyreactive clones with low affinity for HIV-1 envelope (Env) glycoproteins. Polyreactivity analyses showed that 33% of the mucosal antibodies showed similar levels of ELISA reactivity with structurally unrelated non-HIV-1 molecules ([Figure 3](#fig3){ref-type="fig"}A). Polyreactive antibodies also bound to HIV-1 trimeric gp140, gp120, and gp41 proteins ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}A). None of the mucosal antibodies showed reactivity against human epithelial type 2 (HEp-2) cells by the indirect immunofluorescence assay routinely used in clinical diagnostics for autoantibody detection ([Table S2](#mmc3){ref-type="supplementary-material"}). We next tested whether non-HIV antibodies from blood IgA^+^ and IgG^+^ memory B cells of healthy individuals (n = 124) ([@bib55]) recognized HIV-1 Env proteins. IgG antibodies weakly bound to HIV-1 gp140 trimers, gp120, and gp41 subunits with a reactivity pattern consistent with polyreactivity ([Figures 3](#fig3){ref-type="fig"}C and 3D). Of note, the binding intensity to HIV-1 Env proteins, more particularly gp41, was consistently greater than the one measured for non-HIV-1 ligands ([Figures 3](#fig3){ref-type="fig"}B and 3D). Most polyreactive intestinal antibodies from IgA^+^ and IgG^+^ plasmablasts of uninfected individuals (n = 41) ([@bib3]) also reacted against HIV-1 Env glycoproteins (90% against gp140 and gp41) ([Figure 3](#fig3){ref-type="fig"}E). We next determined the relative affinity of polyreactive non-HIV-1 antibodies (18-295, HD1a361, and HD2a57 ([@bib3]), plus historical polyreactive control ED38 ([@bib40])) to YU-2 and ZM96 trimers by surface plasmon resonance (SPR) ([Figures 3](#fig3){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}C). K~D~ values could only be derived for the binding to YU-2 gp140 and ranged from 30.5 to 53.9 nM (versus 0.03--0.2 nM for gp140-specific antibodies; [Figures 3](#fig3){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}C). Compared with high-affinity gp140 antibodies, polyreactive gp140-reactive IgGs displayed about a log decrease of the association rate and a 300-fold faster dissociation to the HIV-1 Env ([Figure 3](#fig3){ref-type="fig"}F). Flow cytometry analyses confirmed the weak, but detectable, binding of polyreactive antibodies to Env proteins exposed at the surface of HIV-1-infected cells ([Figures 3](#fig3){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}D).Figure 3Polyreactivity and Binding to HIV-1 Env Glycoproteins(A) ELISA graphs show the reactivity of mucosal antibodies isolated from HIV-1-infected individuals (n = 72) against keyhole limpet hemocyanin (KLH), double-stranded DNA (dsDNA), insulin, and lipopolysaccharide (LPS). mGO53 (green lines) and ED38 (dotted lines) are negative and positive control antibodies, respectively. Horizontal lines show cutoff optical density 405 (OD~405 nm~) for positive reactivity.(B) Correlation plots comparing the polyreactivity and the reactivity to HIV-1 Env proteins of mucosal antibodies. The y axis indicates the area under the curve (AUC) values of the ELISA binding curves shown in [Figure S4](#mmc1){ref-type="supplementary-material"}A. The x axis indicates cumulative area under the curve (CAUC) values for polyreactivity (polyR) as measured in (A) against all four antigens. Bivariate correlations were estimated with the two-tailed Pearson correlation test. ^∗∗∗∗^p \< 0.0001.(C) ELISA graphs show the reactivity of IgA^+^ and IgG^+^ memory B cell antibodies from healthy individuals hd2 and hd4 (n = 124) ([@bib55]) against trimeric gp140, gp120, and gp41 proteins. mGO53 (green lines) and ED38 (dotted lines) are negative and positive control antibodies, respectively. Horizontal lines show cutoff OD~405 nm~ for positive reactivity. The proportion of antibodies reactive against each HIV-1 protein is shown in pie charts (right), with the total number of antibodies tested indicated in the center.(D) Same as in (B) but for memory B cell antibodies from healthy individuals.(E) Dot plot shows the reactivity of intestinal IgA^+^ and IgG^+^ plasmablast mAbs from healthy individuals (n = 41) ([@bib3]) against trimeric gp140, gp120 and gp41 proteins. The y axis indicates the AUC values of the ELISA binding curves shown in [Figure S4](#mmc1){ref-type="supplementary-material"}B. The dotted line represents the positive threshold, and the percentages of binders are indicated below each group.Mean values from two independent experiments are shown in (A)--(E).(F) (Left) SPR sensorgrams comparing the binding of selected antibodies (n = 7) to trimeric YU-2 gp140 glycoproteins. The y axis shows the resonance units (RU) obtained at a given time (s, seconds) indicated on the x axis. (Right) Dot plots comparing the relative affinity (K~D~) and kinetics constants (k~a~, k~d~) of selected antibodies to trimeric YU-2 gp140 glycoproteins.(G) (Top) Cytograms show the binding of selected IgG antibodies to Gag^+^ YU-2-infected cells. (Bottom). Graph comparing the percentage of antibody binding to YU-2 virions exposed at the surface of infected target cells as measured by flow cytometry. mGO53 is the non-HIV-1 isotype control. Error bars indicate the SEM of triplicate values.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Mucosal HIV-1 Env Antibodies Cross-React with Human Autoantigens {#sec2.4}
----------------------------------------------------------------

Circulating blood and mucosal HIV-1-specific B cell antibodies are often polyreactive and cross-reactive with self-antigens ([@bib46], [@bib72]). The intestinal anti-gp41 IgGs cloned here displayed very weak (6-159 and 64-i109) to marked (6-195) polyreactivity ([Figures 4](#fig4){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). None of the mucosal anti-gp140 showed detectable reactivity against HEp-2-expressing antigens by IFA ([Figure 4](#fig4){ref-type="fig"}B), or immunoblotting (not shown). We next probed the reactivity of the antibodies with microarrays containing more than 9,000 human proteins ([Figures 4](#fig4){ref-type="fig"}C, 4D, and [S5](#mmc1){ref-type="supplementary-material"}B). Binding analyses confirmed the slight polyreactivity of 6-195, characterized by a global shift of the fluorescence signals compared with the isotype control mGO53 ([Figure 4](#fig4){ref-type="fig"}C). Interestingly, three HIV-1 antibodies had strong cross-reactivity to a limited set of human proteins in two independent experiments ([Figures 4](#fig4){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}B). The immunoreactive proteins with the greatest binding (*Z* scores \> 5) were tyrosine-protein phosphatase non-receptor type 2 (PTPN2) and SMAD family members 2 and 3 (SMAD2 and SMAD3) for 6-104; mitogen-activated protein kinase 14 (MAPK14) for 6-195; nudE nuclear distribution gene E homolog like 1 (NDE1); and RUN and FYVE domain-containing 3 (RUFY3) for 64-i109 ([Figures 4](#fig4){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}B). Of note, MAPK14 was also recognized weakly by anti-gp41 antibody 64-i109 (*Z* = 1.2) ([Figure S5](#mmc1){ref-type="supplementary-material"}B). ELISA analyses confirmed MAPK14 cross-reactivity of 6-195 and, to a lesser extent, of 64-i109, whereas no binding was detected for 6-104 and 6-159 ([Figure 4](#fig4){ref-type="fig"}E). Indeed, 6-195 showed high-affinity binding to MAPK14 by SPR with a K~D~ of 26.5 nM ([Figure 4](#fig4){ref-type="fig"}F), whereas no significant interactions were observed with 64-i109 (not shown).Figure 4Cross-Reactivity of Mucosal HIV-1 Antibodies against Human Self-Antigens(A) Bar graph shows the polyreactivity levels of mucosal HIV-1 gp140 antibodies as measured in duplicate by ELISA against KLH, dsDNA, insulin, and LPS in [Figure S5](#mmc1){ref-type="supplementary-material"}A. The x axis indicates cumulative AUC (CAUC) values for polyreactivity (polyR).(B) Antibody binding to HEp-2 cells was assayed by immunofluorescence assay. Ctr^+^, positive control of the kit. mGO53 and ED38 are negative and positive control antibodies, respectively. The scale bars represent 15 μM.(C) Frequency histograms show the log~10~ protein displacement (σ) of the mean fluorescent intensity (MFI) signals for the selected antibodies (n = 9) compared with non-reactive antibody mGO53. The polyreactivity index (PI) corresponds to the Gaussian mean of all array protein displacements.(D) Representative protein microarray plots show the reactivity profile of mucosal anti-gp140 antibodies against human proteins. For each protein spot, the MFI given by the reference (mGO53) and test are depicted on the y and x axes, respectively. Each dot represents the average of duplicate array proteins. The diagonal lines indicate equal binding for reference and test antibodies. Blue dots indicate immunoreactive proteins with a *Z* score \> 5 that were identified in two independent experiments as shown in [Figure S5](#mmc1){ref-type="supplementary-material"}B.(E) Representative ELISA graph comparing the reactivity of mucosal anti-gp140 antibodies to purified MAPK14. mGO53 is the negative control (green). Error bars indicate the SEM of duplicate values.(F) SPR sensorgram showing the binding overtime of 6-195 to purified MAPK14 proteins immobilized on the sensor chip (50 RUs).See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Mucosal and Blood HIV-1 Antibodies Cross-Reacting with MAPK14 Target the gp41 Heptad Repeat 2 Region {#sec2.5}
----------------------------------------------------------------------------------------------------

Clonal variants of HIV-1 B cell lineages can be shared between blood and mucosa compartments ([@bib62], [@bib72]). Circulating and intestinal B cell clones can also target independently the same epitope on HIV-1 Env. We, therefore, wondered whether blood-derived gp41-specific antibodies display cross-reactivity to human antigens, particularly against MAPK14. Nine blood anti-gp41 antibodies isolated from IgG^+^ memory B cells of HIV-1-infected individuals ([@bib48], [@bib65]) were randomly selected for binding to protein microarrays. Most of them recognized conformational epitopes (6-161, 10-137, 10-325, 10-647, 10-679, and 10-1304), whereas 5-25 and 10-1487 bound to the PID peptide ([@bib48], [@bib65]), and 10-437 bound to a linear epitope in the gp41 polar region ([Figure 5](#fig5){ref-type="fig"}A); 6-161 was previously mapped to the C-terminal heptad repeat or heptad repeat 2 (HR2) region of gp41 (gp41^HR2^) ([@bib52], [@bib65]). Cross-competition ELISA experiments confirmed that the epitopes of mucosal 6-195 and 64-i104 and blood 10-325, 10-647, and 10-679 are also located in gp41 HR2 ([Figure 5](#fig5){ref-type="fig"}B). Four of the blood gp41 IgGs showed polyreactivity on protein microarrays, from low to medium (10-679 and 6-161) to very high pan-reactivity as polyreactive control ED38 (10-325 and 10-1487) ([Figures 5](#fig5){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}A). Blood gp41 antibodies did not cross-react with specific human proteins ([Figures 5](#fig5){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}B); 6-161, 10-325, and 10-1487 displayed binding to MAPK14 ([Figure 5](#fig5){ref-type="fig"}C) but were normalized to baseline because of their global pan-reactivity on microarrays ([Figure 5](#fig5){ref-type="fig"}D). Nonetheless, ELISA and SPR analyses confirmed that only anti-gp41^HR2^ antibodies, and no other anti-gp41 IgGs, except highly polyreactive 10-1487 (n = 6), bound with varying affinities to purified recombinant MAPK14 ([Figures 5](#fig5){ref-type="fig"}E and 5F). The apparent affinity (K~D~) of gp41 antibodies 10-679, 6-161, 10-647, 6-195, 10-325, and 10-1487 to MAPK14 ranged from 130 to 10.5 nM ([Figure 5](#fig5){ref-type="fig"}F). MAPK14-reactive anti-gp41^HR2^ antibodies were distinct from previously described polyreactive mucosal antibodies specific to the gp41 cluster I that cross-react with *Escherichia coli* RNA polymerase ([@bib32], [@bib72]) ([Figures S5](#mmc1){ref-type="supplementary-material"}C--S5E).Figure 5Binding of HIV-1 gp41 HR2 Antibodies to MAPK14(A) Representative ELISA graphs show the reactivity of blood anti-gp41 antibodies against overlapping peptides covering the extracellular portion of gp41 (gp41^EC^). The sequences of the peptides recognized are indicated on the top.(B) Representative ELISA graphs show the binding of biotinylated mucosal anti-gp41 to YU-2 gp140 in the presence of potential competitor antibodies (blood-derived anti-gp41 IgG). Error bars indicate the SEM of duplicate values.(C) Protein microarray plots show the reactivity profile of blood anti-gp140 antibodies against human proteins. For each protein spot, the mean fluorescence intensity (MFI) given by the reference (mGO53) and test antibody are depicted on the y and x axes, respectively. Each dot represents the average of duplicate array proteins. The diagonal lines indicate equal binding for reference and test antibodies.(D) Bar graphs comparing the MFI values (Left) and *Z* scores (Right) for the binding of the selected anti-gp41 antibodies to MAPK14 immobilized on the protein array.(E) Representative ELISA graph comparing the reactivity of blood anti-gp140 antibodies to purified MAPK14 proteins. The 6-195 and mGO53 (green) were used as positive and negative control, respectively. Error bars indicate the SEM of duplicate values.(F) Affinity of anti-gp41 antibodies to MAPK14. (Left) Representative SPR curves comparing the binding overtime of selected anti-gp41 IgGs (at 250 nM) to purified MAPK14 immobilized on the sensor chip (250 RUs). (Right) Dot plots comparing the relative affinity (K~D~) of anti-gp41 antibodies to MAPK14. No binding could be detected (ND) for the following antibodies: 5-25, 10-137, 10-437, and 10-1304.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

HIV-1 gp41 HR2 Cluster II Antibodies Bind to MAPK14 via Electrostatic Interactions {#sec2.6}
----------------------------------------------------------------------------------

The gp41 HR2 contains two epitopic clusters, cluster II and VI, the former being frequently targeted by monoclonal antibodies from Env-immunized mice ([@bib17]) and HIV-1 infected humans ([@bib52]). Competition ELISA experiments with mouse anti-cluster II antibody D50 ([@bib17]) confirmed that the epitopes of the anti-gp41^HR2^ IgGs cross-reacting with MAPK14 are located in cluster II ([Figure 6](#fig6){ref-type="fig"}A). Accordingly, D50, as well as previously described human anti-cluster II antibodies 167-D IV ([@bib77]), 98-6 ([@bib22]), and 5F3 ([@bib8]), showed ELISA binding to purified MAPK14 ([Figure 6](#fig6){ref-type="fig"}B). This portion of the HR2 (amino acids 642--665) is enriched in charged and polar residues acids, especially glutamic and aspartic acids ([Figures 6](#fig6){ref-type="fig"}C and 6E), suggesting that cluster II-specific antibodies bind to gp41 via electrostatic interactions. In contrast to polyreactive ED38 and 10-1487 antibodies, anti-gp41^HR2^ IgGs were sensitive to changes in the ionic environment, as evidenced by the decreased ELISA reactivity to MAPK14 with increased salt concentrations ([Figure 6](#fig6){ref-type="fig"}D), indicating that they cross-reacted with MAPK14 through the formation of electrostatic bonds. ELISA binding analyses on Env proteins from different HIV-1 strains showed that E662A substitution affects the reactivity of D50 and 98-6 IgGs but not that of the other anti-gp41^HR2^ cluster II antibodies ([Figure 6](#fig6){ref-type="fig"}E). Although no common peptide sequences unambiguously matched gp41 and MAPK14, structural alignment analysis showed an α helices superimposition identifying a putative mimicry motif (D/ELLE) between gp41^HR2^ cluster II and MAPK14 ([Figure 6](#fig6){ref-type="fig"}F). This peptide candidate is interesting because it encompasses the gp160 residue E662, which is crucial for the binding of D50 and 98-6 antibodies to gp41, and because it contains two aspartic or glutamic acid residues that could promote electrostatic interactions with gp41^HR2^ cluster II IgGs. Nevertheless, because the ELLE motif is short, even if it really contributed to the cross-reactivity of some anti-gp41^HR2^ cluster II antibodies, additional interactions with unidentified homologous protein patches might be involved in the process. Finally, germline versions of 10-325, 6-195, and 64-109 antibodies failed to react with trimeric gp140 and gp41 proteins and simultaneously displayed reduced to abrogated MAPK14 binding, implying that somatic hypermutation is required for the recognition of both HIV-1 gp160 and MAPK14 ([Figure 6](#fig6){ref-type="fig"}G).Figure 6Interactions of Anti-HR2 Cluster II Antibodies with MAPK14(A) Representative ELISA graph shows the binding of biotinylated anti-cluster II D50 antibody to MN gp41 in the presence of potential competitor antibodies (anti-gp41^HR2^ IgGs). mGO53 is the negative control (green).(B) Representative ELISA graph shows the binding of murine (D50) and human (167-D IV, 98-6, and 5F3) anti-cluster II antibodies to purified MAPK14. mGO53 is the negative control (green).(C) Surface representations show the electrostatic potentials of the gp41 cluster II (residues 642--664) (deposited in the Protein Data Base under PDB: [1ENV](pdb:1ENV){#intref0070}) calculated with PyMOL, colored blue (positive electrostatic potential) to red (negative electrostatic potential).(D) Representative ELISA graph shows the area under the curves of OD~405 nm~ values (AUC) for the binding of the selected IgG antibodies to purified MAPK14 in presence of increasing salt concentration.(E) (Top) Amino acid sequence alignment of the gp41 region spanning residues 642--665. Amino acid variations are shown in red. (Bottom) Heat map comparing the mean AUC values for the ELISA binding of anti-gp41 and control antibodies to the selected HIV-1 Env strains (n = 8) as measured in [Figure S7](#mmc1){ref-type="supplementary-material"}. Color intensity is proportional to the reactivity level, with darker-blue colors indicating high binding, whereas light colors show moderate binding (white, no binding).(F) Diagram shows the sequence alignment (Top) based on the structural superposition (Bottom) between a gp41^HR2^ cluster II peptide (red, from PDB: [1ENV](pdb:1ENV){#intref0075}) and MAPK14 (blue, PDB: [5ETI](pdb:5ETI){#intref0080}).(G) ELISA graph comparing the binding of mutated anti-gp41 antibodies (black straight lines) and their germline counterparts (red dotted lines) to trimeric YU-2 gp140, gp41, and MAPK14.Error bars in (A), (B), (D), and (G) indicate the SEM of duplicate values. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In this study, we captured Env-reactive B cells from colorectal tissues of HIV-1-infected patients. The isolated high-affinity gp140 antibodies targeted mainly gp41 and lacked neutralizing activity, potent ADCC breadth, and blocking capacity against HIV-1 transcytosis. In contrast to HIV-1 bNAbs ([@bib37]), mucosal HIV-1 nnAbs did not suppress post-transcytosis infectivity *in vitro*. Although HIV-1 nnAbs may modestly diminish the number of transmitted viruses ([@bib63]), recent reports demonstrated that viral neutralization is required to confer protection against mucosal HIV-1 transmission *in vitro* and *in vivo* ([@bib2], [@bib13]). Moreover, in contrast to certain HIV-1 bNAbs, most nnAbs do not exhibit optimal Fc-dependent antiviral effector functions against T/F-infected cells ([@bib6], [@bib7]) because they cannot interact with the fully closed state of the viral envelope. Nevertheless, anti-PID antibodies, such as 6-159, are able to bind to a substantial fraction of free and cell-associated T/F viruses, most likely via gp41 stumps recognition ([@bib6], [@bib7]). In mucosal tissues, they could participate in eliminating both IgG-bound free virions captured in mucus and HIV-1-infected cells through ADCC and/or antibody-dependent cellular phagocytosis mechanisms. Despite a prototypical anti-PID antibody having been shown to promote *in vivo* clearance of infected cells in humanized mice ([@bib7], [@bib23], [@bib59]), it remains unclear whether mucosal nnAbs have antiviral activity *in situ* and whether they can alter the course of HIV-1 transmission in humans. On the other hand, mucosa-derived milk anti-gp120 IgG antibodies have antiviral properties and could decrease HIV-1 transmission from infected, lactating women to infants ([@bib18], [@bib39]). Recombinant mucosal gp120-specific IgGs produced from milk-resident B cells may be neutralizing or ADCC potent ([@bib20], [@bib24], [@bib62]). Hence, although gut and mammary gland compartments share certain B cell clones ([@bib34]), the nature, magnitude, and quality of humoral responses to HIV-1 likely differ at distinct mucosal sites.

We show that a substantial proportion of gp140-captured intestinal B cell antibodies from infected individuals reacted with low affinity to HIV-1 Env proteins. This suggests a very low frequency of high-affinity gp160 B cells in rectosigmoid tissues and, conversely, an abundance of non-HIV-1 affinity-matured and polyreactive mucosa-homing memory B cells and plasmablasts ([@bib3], [@bib9], [@bib19]). Alternatively, it cannot be excluded that the baiting strategy, based on the recognition of a single viral strain-derived, foldon-stabilized gp140 trimers with an "open" conformational state, was not fully efficient for the isolation of the entire population of high-affinity HIV-1 B cells from the gut. Interestingly, we found that HIV-1 Env glycoproteins were also weakly recognized by polyreactive and somatically mutated blood and intestinal B cell antibodies from HIV-1-naive individuals. Polyreactive antibodies bound particularly well to the gp41 moiety. This is in agreement with the works of Haynes and colleagues ([@bib72], [@bib76]) showing that polyreactive and commensals-reactive B cells can cross-react with gp140, particularly the gp41 protein, even though none of the gp41-reactive antibodies described here expressed the V~H~1-69 gene previously associated with mucosal gp41 antibody responses ([@bib72], [@bib76]). In fact, it has been speculated that pre-activated, mutated, memory B cells residing in the gut before the infection are recruited through polyreactive binding to gp41 and ultimately mature toward HIV-1 Env. This phenomenon of "immune diversion" at mucosal sites could thus be responsible for the predominance of naturally and vaccine-induced gp41 antibodies toward non-neutralizing HIV-1 epitopes ([@bib72], [@bib76]). Apart from polyreactivity to protein moieties, antibody cross-reactivity against glycan subunits common to the viral envelope and bacteria outer membrane could also mediate HIV-1 recognition by pre-existing gut antimicrobial B cells. The binding to mannose repeats on HIV-1 Env trimers by human blood and intestinal monoclonal antibodies targeting the *Klebsiella pneumoniae* lipopolysaccharide O3-antigen have indeed been recently reported ([@bib60]). Besides this potential immune diversion because of pre-existing poly- and glycans-reactive B cells, other phenomena, such as germinal center fade-out, B cell dysregulation ([@bib30]), bacterial translocation, and local inflammation ([@bib27]), certainly compromise gut B cell responses in infected individuals. Ileum-resident plasmablasts and memory B cells in HIV-1-infected individuals have been shown to contain very few HIV-1-specific cells ([@bib72]). ART regimen early during the acute phase may be beneficial in preserving B cell immunity at mucosal sites ([@bib53]). Interestingly, we found high-affinity gp140 antibodies more frequently in the eART donor, but studies on more donors are needed to confirm that observation.

Molecular mimicry between HIV-1 and normal human proteins was described at a serological level more than 30 years ago ([@bib4], [@bib68]). The use of HIV-1 gp160 monoclonal antibodies produced from HIV-1-infected and vaccinated individuals has allowed researchers to identify several gp120/gp41 cross-reactive epitopes in microbial and human enzymes ([@bib35], [@bib72], [@bib76], [@bib78]). Similarly, we found here that mucosal anti-gp140 has the capacity to cross-react against human intracellular autoantigens SMAD2/3 transcription factors, RUFY3 protein adaptor, NDEL1 oligopeptidase, PTPN22 phosphatase, and MAPK14 kinase. That intestinal HIV-1 antibodies recognized these proteins, expressed to different degrees in circulating mononuclear cells or the gut, could be fortuitous and because of sequence and/or structural homology. The cross-reactivity to MAPK14 is intriguing because the MAPK14/p38 signaling pathway is a master regulator of various cellular activities, with some implicated in HIV-1 replication and pathogenesis, such as T cell and mucosal epithelial cell apoptosis ([@bib21], [@bib50], [@bib74]). One pathological immune consequence of CD4^+^ T cell apoptosis is the cross-presentation of self-antigens capable of inducing autoreactive CD8^+^ T cell responses ([@bib57]). Whether CD4^+^ T cell apoptosis could lead to the presentation of self-antigens to B cells, including MAPK14, is currently unknown. We showed here that both blood and mucosal anti-gp41^HR2^ cluster II antibodies cross-react with nanomolar affinity against MAPK14. This is particularly interesting because the circulating memory B cell repertoire to HIV-1 gp41 is largely enriched with clones targeting the gp41^HR2^ ([@bib52]). Regrettably, because of the conformational nature of the antigenic determinants recognized by anti-cluster II IgG, we could not map the targeted epitopes on both HIV-1 gp140 and MAPK14 and, therefore, could not precisely pinpoint the homology motifs. Whether these antibodies with a MAPK14-binding potential *in vivo* could have pathological effects in infected humans is unclear because MAPK14 is a cytoplasmic and nuclear protein, probably not accessible to antibodies.

Immune tolerance control would normally proscribe HIV-1 B cells reacting strongly enough with self-antigens. However, HIV-1-associated immune perturbations often lead to serum autoantibody production ([@bib44], [@bib46]), suggesting that B cell tolerance mechanisms are somehow defective or relaxed in infected humans ([@bib5], [@bib44], [@bib67]). The loss of regulatory T cells and/or their anergy-prone state is certainly a key factor facilitating the emergence of autoreactive B cell clones during HIV-1 infection ([@bib43]). Clones expressing a B cell receptor with a dual reactivity to HIV-1 and self-antigens could also be redeemed from tolerance purge via the selection of antibody mutations' increasing affinity to HIV-1 Env but disfavoring high autoantigen binding ([@bib10], [@bib25], [@bib26]). Accumulating data from human ([@bib58], [@bib61], [@bib70]) and mouse models ([@bib61], [@bib10]) converge toward the existence of such a "B cell redemption" mechanism, which permits the recruitment of autoreactive clones during the germinal center reaction in response to natural infection or vaccination. However, it is not clear whether HIV-1-induced chronic, antigenic stimulation and immune dysregulation would not interfere with clonal redemption mechanisms. Self-reactivity has been linked to the maturation of HIV-1-specific clones toward enhanced affinity and neutralization ([@bib1], [@bib33], [@bib56]). Mutating away from self-binding without losing optimal interactions with viral antigens may, therefore, be difficult. Because of the nature of its Env glycoproteins, recognized by both poly-reactive and cross-reactive B cells, it is, thus, tempting to speculate that HIV-1 could divert the mucosal B cell response toward the generation of poorly functional antibodies to immunodominant epitopes unable to control viral transmission and dissemination. This is an attractive scenario that demands to be further investigated.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Human monoclonal IgG PGT128[@bib49]N/AHuman monoclonal IgG 10-1074[@bib49]N/AHuman monoclonal IgG 3BNC117[@bib66]N/AHuman monoclonal IgG 5-25[@bib65]N/AHuman monoclonal IgG 6-161[@bib65]N/AHuman monoclonal IgG 6-161 GLThis paperN/AHuman monoclonal IgG 10-137[@bib48]N/AHuman monoclonal IgG 10-325[@bib48]N/AHuman monoclonal IgG 10-437[@bib48]N/AHuman monoclonal IgG 10-647[@bib48]N/AHuman monoclonal IgG 10-679[@bib48]N/AHuman monoclonal IgG 10-1304[@bib48]N/AHuman monoclonal IgG 10-1487[@bib48]N/AHuman monoclonal IgG/IgA 6-195This paperN/AHuman monoclonal IgG 6-195 GLThis paperN/AHuman monoclonal IgG 64-i109This paperN/AHuman monoclonal IgG 64-i109 GLThis paperN/AHuman monoclonal IgG 18-295This paperN/AHuman monoclonal IgG ED38[@bib40]N/AHuman monoclonal IgG mGO53[@bib75]N/AMouse monoclonal IgG D50[@bib17]; NIH AIDS Reagent ProgramCat\#11393Human monoclonal IgG/IgA 6-159This paperN/AHuman monoclonal IgG 6-104This paperN/AHuman monoclonal IgG 558-2[@bib32]N/AHuman monoclonal IgG DH308[@bib72]N/AHuman monoclonal IgG DH307[@bib72]N/AHuman monoclonal IgG 167-D IV[@bib77], NIH AIDS Reagent ProgramCat\#11681Human monoclonal IgG 98-6[@bib22], NIH AIDS Reagent ProgramCat\#1240Human monoclonal IgG 5F3[@bib8], NIH AIDS Reagent ProgramCat\#6882Mouse anti-human CD38-APC (HIT2)BD biosciencesCat\#555462Mouse anti-human CD21 BV421 (B-ly4)BD biosciencesCat\#562966Mouse anti-human CD27 PE-CF594 (M-T271)BD biosciencesCat\#562297Mouse anti-human CD19 Alexa Fluor 700 (HIB19)BD biosciencesCat\#557921Mouse anti-human CD24 PE-Cy7 (ML5)BD biosciencesCat\#561646Mouse anti-human CD10 BV650 (HI10a)BD biosciencesCat\#563734Mouse anti-human IgD APC-H7 (IA6-2)BD biosciencesCat\#561305Mouse anti-human IgM BV605 (G20-127)BD biosciencesCat\#562977Mouse anti-human IgG BV786 (G18-145)BD biosciencesCat\#564230Mouse anti-human CD138 BV711 (MI15)BD biosciencesCat\#563184Mouse anti-human IgA FITC (IS11-8E10)Miltenyi BiotecCat\#130-113-475Goat anti-human IgG Alexa Fluor 647Life technologiesCat\#A-21445Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ fragment specificJackson ImmunoReseachCat\#109-035-098Peroxidase AffiniPure Goat Anti-Human IgA/IgG/IgM (H+L)Jackson ImmunoReseachCat\#109-035-064Blood human monoclonal IgGs from healthy individuals (hd2 & hd4)[@bib55]N/AIntestinal human monoclonal IgGs from healthy individuals (e.g., HD1a361 and HD2a57)[@bib3]N/A**Bacterial and Virus Strains**NEB 10-beta Competent *E.coli*New England BiolabsC3019HLab adapted HIV-1 virus (NLAD8)NIH AIDS Reagent ProgramCat\#11346Lab adapted HIV-1 virus (NL4.3)NIH AIDS Reagent ProgramCat\#7407Lab adapted HIV-1 virus (YU-2)NIH AIDS Reagent ProgramCat\#1350Transmitted/founder HIV-1 virus (WITO)NIH AIDS Reagent ProgramCat\#11739Transmitted/founder HIV-1 virus (CH058)NIH AIDS Reagent ProgramCat\#11856Transmitted/founder HIV-1 virus (CH077)NIH AIDS Reagent ProgramCat\#11742Transmitted/founder HIV-1 virus (CH0106)NIH AIDS Reagent ProgramCat\#11743Transmitted/founder HIV-1 virus (REJO)NIH AIDS Reagent ProgramCat\#11746Transmitted/founder HIV-1 virus (RHPA)NIH AIDS Reagent ProgramCat\#11744**Biological Samples**Colorectal biopsies from HIV-1^+^ individualsCentre Hospitalier Regional d'Orléans, FranceN/APeripheral blood mononuclear cells (PBMCs) & sera from HIV-1^+^ individualsCentre Hospitalier Regional d'Orléans, FranceN/A**Chemicals, Peptides, and Recombinant Proteins**AviTagged clade B YU-2 gp140 trimers[@bib65]N/AYU-2 gp120[@bib65]N/AYU-2 gp120^D368R^[@bib65]N/AYU-2 gp120^I420R^[@bib65]N/AClade B HXBc2 gp120^core^ proteins[@bib65]N/AClade B MN gp41 proteinNIH AIDS Reagent ProgramCat\#12027Clade B SF162 trimeric gp140NIH AIDS Reagent ProgramCat\#12026Clade D UG021 trimeric gp140NIH AIDS Reagent ProgramCat\#12065Clade A UG037 trimeric gp140NIH AIDS Reagent ProgramCat\#12063Clade F BR029 trimeric gp140NIH AIDS Reagent ProgramCat\#12066Clade C/B' CN54 trimeric gp140NIH AIDS Reagent ProgramCat\#12064Clade C ZM96 trimeric gp140[@bib56]N/AConsensus clade B 15-mer overlapping peptide libraryNIH AIDS Reagent ProgramCat\#9480*E. coli* RNA polymerase α subunit (RNApol α)This paperN/AHuman recombinant MAPK14 (p38 α)BPS BioscienceCat\#40070Recombinant human mucin 2MyBioSourceCat\#MBS958652Purified double stranded (ds)-DNASigma-AldrichCat\#D1501Purified Hemocyanin - Keyhole Limpet (KLH)Sigma-AldrichCat\#H8283Purified Lipopolysaccharides (LPS)Sigma-AldrichCat\#L2637Purified InsulinSigma-AldrichCat\#I9278FITC-labeled DEAE-dextranMolecular ProbesCat\#95648Peroxidase-conjugated streptavidinBD BiosciencesCat\#554066PolyethyleniminePolysciences23966-2LIVE∕DEAD fixable aqua dead cell stain kitThermo Fisher ScientificCat\#L34957SuperScript IV reverse transcriptaseThermo Fisher ScientificCat\#18091200ReadiUse ABTS Substrate SolutionEuromedexCat\#11001-AATStreptavidin R-PE conjugateThermo Fisher ScientificCat\#SA10041**Critical Commercial Assays**EZ-Link Sulfo-NHS-LC-Biotinylation kitThermo Fisher ScientificCat\#21435BirA biotin-protein ligase bulk reaction kitAvidity, LLCCat\#bulk BirAHIV-1 p24 Antigen Capture AssayAdvanced Bioscience Laboratories IncCat\#5421Amine Coupling KitBiacore, GE HealthcareCat\# BR100050ANA HEp-2 AeskuSlides®Aesku.DiagnosticsCat\#51.100FUGENE-6 transfection reagentPromegaCat\# E2691**Experimental Models: Cell Lines**TZM-bl cellsNIH AIDS Reagent ProgramCat\# 8129Epithelial monolayer-forming human endometrial carcinoma type A HEC-1A cellsATCC^®^Cat\# HTB-112Freestyle 293-F cellsThermo Fisher ScientificCat\#R79007CEM.NKR CCR5^+^ cellsNIH AIDS Reagent ProgramCat\#4376**Oligonucleotides**IgH PCR primers[@bib75], [@bib71], [@bib3]N/AIgK PCR primers[@bib75], [@bib71]N/AIgL PCR primers[@bib75], [@bib71]N/A**Recombinant DNA**pSG3ΔEnv vectorNIH AIDS Reagent ProgramCat\#11051pcDNA3.1/Zeo^(+)^ expression vectorThermo Fisher ScientificCat\#V86020HIV-1 Env Expression Vector (Bal.26)NIH AIDS Reagent ProgramCat\#11446HIV-1 Env Expression Vector (6535.3)NIH AIDS Reagent ProgramCat\#11017HIV-1 Env Expression Vector (YU-2)NIH AIDS Reagent ProgramCat\#12133HIV-1 Env Expression Vector (SC422661.8)NIH AIDS Reagent ProgramCat\# 11058HIV-1 Env Expression Vector (PVO.4)NIH AIDS Reagent ProgramCat\# 11022**Software and Algorithms**GraphPad Prism software (v6.0a)GraphPad Prism Inc.<https://www.graphpad.com/>FlowJo software (v10.3)FlowJo LLC<https://www.flowjo.com/solutions/flowjo>BIAevaluation software (v4.1.1)Biacore, GE Healthcare<https://www.biacore.com/lifesciences/service/downloads/software_licenses/biaevaluation/>UCSF Chimera software (v1.9)[@bib42]<https://www.cgl.ucsf.edu/chimera/download.html>ZEN imaging software (Zen 2.0 blue version)Zeiss<https://www.zeiss.com/microscopy/int/products/microscope-software/zen-lite/zen-lite-response.html>Spotxel® softwareSICASYS Software GmbH<https://www.sicasys.de/spotxel/>ProtoArray® Prospector software (v5.2.3)Thermo Fisher Scientific<https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-assays-analysis/protein-microarrays/technical-resources/data-analysis.html>.GenePix Pro 6.0 softwareMolecular Devices[http://mdc.custhelp.com/app/answers/detail/a_id/18691/∼/genepix%C2%AE-pro-6-microarray-acquisition-%26-analysis-software-download-page](http://mdc.custhelp.com/app/answers/detail/a_id/18691/%7E/genepix%C2%AE-pro-6-microarray-acquisition-%26-analysis-software-download-page){#intref0045}**Other**CM5 chipsBiacore, Inc.BR-1000-12Peptide M-coupled agarose beadsInvivogenCat\#gel-pdm-5Protein G Sepharose 4 fast flow beadsGE HealthcareCat\#17061805HisPur Cobalt agarose beadsThermo Fisher ScientificCat\#25228ProtoArray Human Protein MicroarraysThermo Fisher ScientificCat\#PAH0525101Superdex® 200 increase 10/300 GL columnGE HealthcareCat\#GE28-9909-44

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Hugo Mouquet (<hugo.mouquet@pasteur.fr>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human samples {#sec4.3.1}

Samples were obtained as part of the BHUANTIVIH research protocol performed in accordance with and after ethical approval from all the French legislation and regulation authorities. Peripheral blood mononuclear cells (PBMC), sera and colon biopsies (collected by retroscopy procedure) were obtained from HIV-1 infected patients at the Centre Hospitalier Regional d'Orléans. Five HIV^+^ donors (4 males and 1 female) with a median age of 48 years (range, 27-55 years) were included in the study, and were either untreated (n = 1) or treated by ART (n = 4) at the time of the blood/colon sampling. The HIV status and main clinical characteristics of the donors are summarized in [Table S1](#mmc2){ref-type="supplementary-material"}. The clinical research protocol received approval from the *Comité Consultatif pour le Traitement de l'Information en matière de Recherche dans le domaine de la Santé* (CCTIRS) on December 12^th^ 2013, the *Commission Nationale de l'Informatique et des Libertés* (CNIL) on August 8^th^ 2014 and the *Comité de Protection des Personnes de Tours* (CPP Région Centre-Ouest 1) on December 17^th^ 2014. All donors gave written consent to participate in this study, and data were collected under pseudo-anonymized conditions using subject coding. Ethical issues have been monitored by the Ethics Board for European contracts, an *ad hoc* independent Ethics Committee in charge of reviewing periodically sensitive ethical issues in EU funded researches when requested by the EU.

Method Details {#sec4.4}
--------------

### Antigens and antibody controls {#sec4.4.1}

HIV-1 antigens: AviTagged clade B YU-2 gp140 trimers, YU-2 gp120, YU-2 gp120^D368R^, YU-2 gp120^I420R^, clade B HXBc2 gp120^core^ proteins ([@bib65]), and clade C ZM96 trimeric gp140 ([@bib56]) were produced by transient transfection of exponentially growing Freestyle 293-F suspension cells (Thermo Fisher Scientific, Waltham, MA) using polyethylenimine (PEI)-precipitation method, purified by affinity chromatography using HisPur Cobalt agarose beads (Fisher Scientific), and controlled for purity by SDS-PAGE and NativePAGE gel staining as previously described ([@bib36], [@bib71]). The trimeric state of purified YU-2 gp140 was further confirmed by size exclusion FPLC-chromatography using an AKTA pure FPLC instrument (GE Healthcare) with a Superdex® 200 increase 10/300 GL column (GE Healthcare). YU-2 trimers used for B cell FACS capture were biotinylated using BirA biotin-protein ligase bulk reaction kit (Avidity, LLC). Purified clade B MN gp41 protein (\#12027), SF162 (\#12026), UG021 (\#12065), UG037 (\#12063), BR029 (\#12066), CN54 (\#12064) gp140 trimers and consensus clade B 15-mer overlapping peptide library (\#9480) were provided by the NIH AIDS Reagent Program (Germantown, MD). The *E. coli* RNA polymerase α subunit (RNApol α) was produced and purified as described above for HIV-1 proteins using a codon-optimized DNA fragment (containing nucleotide sequences encoding the IgK leader peptide, the RNApol α, and an hexahistidine tag) cloned into pcDNA3.1/Zeo^(+)^ expression vector.

Human HIV-1 antibodies are as follow: bNAbs anti-V3/glycans PGT128 and 10-1074 ([@bib49]), anti-CD4bs 3BNC117 ([@bib66]), and 13 previously characterized anti-gp41 antibodies ([@bib32], [@bib48], [@bib65], [@bib72]). Non-HIV-1 antibodies include polyreactive and non-polyreactive antibody ED38 ([@bib40]) and mGO53 ([@bib75]), respectively; healthy individuals' blood (from hd2 and hd4 donors \[[@bib55]\]) and polyreactive mucosal (from HD1-3 donors, [@bib3]\]) monoclonal IgGs. Recombinant IgG antibodies were produced by co-transfection of Freestyle 293-F cells (Thermo Fisher Scientific, Waltham, MA) using PEI-precipitation method as previously described ([@bib36], [@bib71]), and purified by affinity chromatography using protein G Sepharose 4 fast flow beads (GE Healthcare). Purified antibodies were biotinylated using the EZ-Link Sulfo-NHS-Biotin kit (Thermo Fisher Scientific). Anti-gp41^HR2^ monoclonal antibodies previously generated from immunized mice (D50 ([@bib17]), \#11393), and from HIV-seropositive subjects (167-D IV ([@bib77]), \#11681; 98-6 ([@bib22]), \#1240; and 5F3 ([@bib8]), \#6882) were obtained through the NIH AIDS Reagent Program (Germantown, MD).

### Mucosal cells isolation and flow cytometry immunophenotyping {#sec4.4.2}

Intraepithelial lymphocytes (IEL) were isolated by two rounds of vigorous shaking in DMEM-Glutamax (GIBCO, Thermo Fisher Scientific) supplemented with 1% Fetal Bovine Serum (FBS) (GIBCO), 1mM EGTA and 1.5 mM MgCl~2~. Lamina propria lymphocytes (LPL) were isolated by two rounds of tissue digestion in medium containing collagenase II 100U/ml (Sigma, Saint-Louis, MO), followed by mechanical disruption with a syringe equipped with an 16-gauge blunt-end needle. Both IEL and LPL were washed in DMEM - Glutamax (GIBCO) supplemented with 10% FBS (GIBCO), 1% penicillin and 1% streptomycin (GIBCO). Cells were then stained for flow cytometry analyses and single-cell sorted as follow. Cells were first stained using LIVE∕DEAD fixable dead cell stain kit (405 nm excitation) (Molecular Probes, Thermo Fisher Scientific) to exclude dead cells. Cells were then incubated for 30 min at 4°C with biotinylated recombinant YU2 gp140 trimers ([@bib48], [@bib66]). Cells were washed once with 1% FBS-PBS (FACS buffer), and incubated for 30 min at 4°C with a cocktail of mouse anti-human antibodies: CD19 A700 (HIB19, BD Biosciences, San Jose, CA), CD38 APC (HIT2, BD Biosciences), CD21 BV421 (B-ly4, BD Biosciences), CD27 PE-CF594 (M-T271, BD Biosciences), CD24 PE-Cy7 (ML5, BD Biosciences), CD10 BV650 (HI10a, BD Biosciences), IgD APC-H7 (IA6-2, BD Biosciences), IgM BV605 (G20-127, BD Biosciences), IgG BV786 (G18-145, BD Biosciences), CD138 BV711 (MI15, BD Biosciences), IgA FITC (IS11-8E10, Miltenyi Biotec, Bergisch Gladbach, Germany), and streptavidin R-PE conjugate (Invitrogen, Thermo Fisher Scientific). Finally, cells were washed with FACS buffer and resuspended in 1mM EDTA FACS buffer. Following a lymphocyte and single cell gating, live cells were gated on CD19^+^ B cells. FACS analyses were performed using a FACS Aria II cytometer (BD Biosciences) and FlowJo software (v10.3, FlowJo LLC, Ashland, OR).

### Single B cell FACS sorting and expression-cloning of antibodies {#sec4.4.3}

Single CD19^+^IgA^+^ and CD19^+^IgG^+^ B cells were identified as described above and sorted into 96-well PCR plates using a FACS Aria III sorter (Becton Dickinson, Franklin Lakes, NJ) as previously described ([@bib71]). Single-cell cDNA synthesis using SuperScript IV reverse transcriptase (Thermo Fisher Scientific) followed by nested-PCR amplifications of IgH, Igκ and Igλ genes, and sequences analyses for Ig gene features were performed as previously described ([@bib71]). For the reversion to germline (GL) of the selected anti-gp41 antibodies, sequences were constructed by replacing the mutated V~H~-(D~H~)-J~H~ and V~L~-J~L~ gene segments with their GL counterparts as previously described ([@bib49]). Purified digested PCR products were cloned into human Igγ~1~-, Igα~1~-, Igα~2~-, Igκ- or Igλ-expressing vectors as previously described ([@bib36], [@bib71]). Recombinant antibodies were produced by transient co-transfection of Freestyle 293-F suspension cells (Thermo Fisher Scientific) using PEI-precipitation method as previously described ([@bib36], [@bib71]). Recombinant human antibodies and serum IgG from HIV-1 donors were purified by batch/gravity-flow affinity chromatography using peptide M-coupled agarose (Invivogen, San Diego, CA) and protein G Sepharose 4 fast flow beads (GE Healthcare, Chicago, IL) for IgAs and IgGs, respectively. Mucosal gp140 antibodies were biotinylated as described above.

### ELISAs {#sec4.4.4}

Antibody bindings to HIV-1 envelope antigens and human mucin 2 were measured as previously described ([@bib48], [@bib49]): high-binding 96-well ELISA plates (Costar, Corning) were coated overnight with 125 ng/well of purified HIV-1 envelope proteins or purified recombinant human mucin 2 (MyBioSource, Inc., San Diego, CA). After washings, plates were blocked 2 h with 2% BSA, 1mM EDTA, 0.05% Tween 20-PBS (Blocking buffer), washed, and incubated with serially diluted IgG/IgA antibodies and serum IgG in PBS for HIV-1 proteins. Polyreactivity ELISA was performed as previously described ([@bib55]). Briefly, high-binding 96-well ELISA plates (Costar, Corning, Corning, NY) were coated overnight with 500 ng/well of purified double stranded (ds)-DNA, KLH, LPS (Sigma), 250 ng/well of insulin (Sigma), and 125 ng/well of HIV-1 proteins in PBS. After blocking and washing steps, purified IgG antibodies were tested in at 4 μg/ml and 3 consecutive 1:4 dilutions in PBS. Control antibodies, mGO53 (negative), and ED38 (high positive) were included in each experiment. After washings, the plates were revealed by incubation for 1 h with goat HRP-conjugated anti-human IgG or anti-human IgG/IgM/IgA antibodies (Immunology Jackson ImmunoReseach, 0.8 μg/ml final), and by adding 100 μl of HRP chromogenic substrate (ABTS solution, Euromedex) after washing steps. After 1 h incubation, optical densities were measured at 405nm (OD~405nm~), and background values given by incubation of PBS alone in coated wells were subtracted. Experiments were performed using HydroSpeed microplate washer and Sunrise microplate absorbance reader (Tecan Männedorf, Switzerland). For competition ELISAs, YU-2 gp140- and MN gp41-coated plates were blocked, washed, incubated for 2 h with biotinylated antibodies (at a concentration 0.33 nM) in 1:2 serially diluted solutions of antibody competitors in PBS (IgG concentration range from 1 to 133 nM), and developed as described above using HRP-conjugated streptavidin (BD Biosciences) (at 0.8 μg/ml in blocking buffer). High-binding 96-well ELISA plates (Costar, Corning) were coated overnight with purified recombinant MAPK14 (250 ng/well; Tebu-bio, Le Perray-en-Yvelines, France) and *E. coli* RNApol α (500 ng/well), and binding of HIV-1 antibodies was tested in the experimental conditions of our previously described peptide-ELISA method ([@bib47]). Binding of anti-gp140 antibodies to gp41 peptides (NIH Reagent Program) was tested using the same procedure as in ([@bib47]). To determine the ionic strength dependence of the antibody-antigen interactions, MAPK14 ELISAs were performed as described above but with antibodies diluted in 10 mM HEPES pH 7.3 containing different concentrations of NaCl -- 0.125, 0.25, 0.5, and 1 M. All antibodies were tested in duplicate (excepted for the polyreactivity testing of non HIV-1 antibodies) in at least two independent experiments, which included mGO53 negative and appropriate positive controls.

### HIV-1 virus production and *in vitro* neutralization assay {#sec4.4.5}

Pseudoviruses (Bal.26, 6535.3, YU-2, SC422661.8 and PVO.4; Env plasmids obtained from the NIH AIDS reagent program) were prepared by cotransfection of 293T cells with pSG3ΔEnv vector using FUGENE-6 transfection reagent (Promega, Madison, WI) as previously described ([@bib31], [@bib64]). Pseudoviruses-containing culture supernatants were harvested 2 days post-transfection and 50% tissue culture infectious dose (TCID50) of each preparation was determined using TZM-bl cells as previously described ([@bib31], [@bib64]). Neutralization of cell-free HIV-1 was measured using TZM-bl cells as previously described ([@bib31], [@bib64]). The 50% inhibitory concentration (IC~50~) values were calculated using GraphPad Prism software (v6.0a, GraphPad Prism Inc., USA) by fitting duplicate values using the 5-parameters sigmoidal dose-response model. Neutralization experiments were performed twice and included mGO53 negative control.

### *In vitro* viral transcytosis assay {#sec4.4.11}

Transcytosis assays were performed using epithelial monolayer-forming human endometrial carcinoma type A HEC-1A cells (ATCC^®^ HTB-112) cultivated on 0.4 μm polyethylene terephthalate transwell membranes (Millicell^®^, Millipore) as recently described ([@bib37]). Briefly, the confluence, tightness and integrity of HEC-1A monolayers were controlled by measuring the transepithelial electrical resistance, the paracellular permeability to 40 kDa FITC-labeled DEAE-dextran (Molecular Probes) and by assaying the expression of tight junction proteins by confocal microscopy as previously described ([@bib37]). HIV-1 viruses (10 ng of p24 HIV-1 NLAD8) were incubated v/v for 1 h at 37°C with purified antibodies (66.67 nM final concentration), and mixtures were added onto HEC-1A monolayers at day 6 of culture. As controls, HIV-1 alone was added into inserts with cells (No Ab) and without cells (CTL), which takes into account the proportion of virions not passing through the transwell filter. After 24 h, basal media were collected and their p24 content measured by ELISA (HIV-1 p24 Antigen Capture Assay, Advanced Bioscience Laboratories Inc., Rockville, MD). The percentage of transcytosis was determined using the following formula: (concentration p24 sample / mean concentration p24 CTL)^∗^100. The infectivity of virions transcytosed in the presence or not of antibodies (0.05 ng p24) was measured using a previously described TZM-bl cells assay ([@bib37]). Two independent experiments were performed in quadruplicate, and included negative (mGO53) and positive (10-1074) controls.

### Flow cytometry binding analysis to infected cells {#sec4.4.6}

Laboratory-adapted (NL4.3, AD8 and YU-2) and T/F (WITO, CH058, CH077, CH0106, REJO and RHPA) ([@bib51]) viruses were produced from infectious molecular clones (NIH AIDS Reagent Program) as previously described ([@bib11]). CEM-NKR-CCR5 cells (NIH AIDS Reagent Program) were infected with inocula of selected viruses, and adjusted to achieve 10%--30% of Gag^+^ cells at 48 h post infection ([@bib6], [@bib7]). Infected cells were incubated with IgG antibodies (at 15 μg/ml) in staining buffer (PBS, 0.5% BSA, 2mM EDTA) for 30 min at 37°C, washed and incubated 30 min at 4°C with AF647-conjugated anti-human IgG antibodies (1:400 dilution; Life technologies). Cells were then fixed with 4% paraformaldehyde and stained for intra-cellular Gag as previously described ([@bib6], [@bib7]). Data were acquired using an Attune Nxt instrument (Life Technologies) and analyzed using FlowJo software (v10.3; FlowJo LLC).

### Viral capture assay {#sec4.4.12}

High-binding 96-well ELISA plates (Costar, Corning) were coated overnight with goat anti-human IgG antibodies (250 ng/well, Jackson Immunoreasearch) in PBS. After washings in PBS, plates were blocked 2 h with 5% non-fat dry milk in PBS, and then incubated 2 h with 500 ng/well of IgGs in PBS. After three washes, 10 ng p24 HIV-1 virions in 10%FBS-DMEM medium (GIBCO, Life technologies) were added *per* well. Plates were incubated 4 h at 37°C, extensively washed with PBS and captured HIV-1 virions were lysed with 100 μl of lysis buffer (100μl/well, Advanced Bioscience Laboratories Inc.). The amount of captured virions was determined as p24 content using the HIV-1 p24 Antigen Capture Assay (Advanced Bioscience Laboratories Inc.) according to the manufacturer's instructions. Samples were analyzed in quadruplicate.

### ADCC assay {#sec4.4.7}

The ADCC assay was performed as previously described ([@bib6], [@bib7]). Briefly, 2 × 10^4^ HIV-1-infected CEM-NKR cells stained with Far-Red cell tracker (Life Technologies) were incubated with antibodies (at 15 μg/ml) for 5 min at room temperature. Primary NK cells (2 × 10^5^) were added to each well, with a ratio of 1 CEM-NKR cell to 10 NK cells. Plates were then spun for 1 min at 300 g and incubated at 37°C for 4 h. After fixation with 4% PFA for 10 min, cells were stained for intracellular Gag as previously described ([@bib6], [@bib7]). Data were acquired on an Attune Nxt instrument (Life Technologies) and analyzed using FlowJo software (v10.3; FlowJo LLC). The frequencies of Gag^+^ cells among Far-Red^+^ cells were determined. ADCC was calculated by using the following formula: 100 × (% of Gag^+^ target cells *plus* NK cells without antibody - % of Gag^+^ target cells *plus* effector cells with antibody) / (% of Gag^+^ target cells *plus* NK cells without antibody). Negative values were set to zero. mGO53 negative control was included in each experiment.

### SPR binding assay {#sec4.4.8}

To measure the apparent affinity of IgG antibodies to YU-2 and ZM-96 trimers, CM5 chips (Biacore, Inc.) were immobilized by using Amine Coupling Kit (Biacore, GE Healthcare) to reach immobilization levels of 600 and 800 RUs, respectively. MAPK14 was immobilized in the same conditions to reach 50 and 250 RUs immobilization levels. IgGs at a concentration of 1 μM (for 18-295, HD1a361 and HD2a57), 0.5 μM (for ED38), 125 nM (for 64-i109) or 62.5 nM (for 6-104 and 6-195) for HIV-1 trimers and 250 nM of each antibody for MAPK14, and 6-8 successive 1:2 dilution in HBS-EP+ running buffer (Biacore, GE Healthcare) were injected through flow cells at flow rates of 30 μl/min with 3 min association and 4 min dissociation. The sensor surface was regenerated between each experiment with a 30-60 s injection of 4 M MgCl~2~ and 1M NaCl-0.05 M NaOH for HIV-1 Env- and MAPK14-immobilized chips, respectively. All experiments were performed with a Biacore 2000 (Biacore, GE Healthcare) at 25°C. Evaluation of kinetic data was performed using the BIAevaluation software (v4.1.1, Biacore, GE Healthcare) by applying 1:1 binding Langmuir model or alternatively, using equilibrium analyses when the 1:1 fitting was not possible.

### HEp-2 IFA {#sec4.4.9}

Recombinant mucosal IgG antibodies and control antibodies (mGO53 and ED38) at 150 μg/ml were analyzed by indirect immunofluorescence assay (IFA) on HEp-2 cells sections (ANA HEp-2 AeskuSlides®, Aesku.Diagnostics, Wendelsheim, Germany) using the kit's controls and FITC-conjugated anti-human IgG antibodies as the tracer according to the manufacturer' instructions. Sections were examined using the fluorescence microscope Axio Imager 2 (Zeiss, Jena, Germany) with ApoTome.2 system, and pictures were taken at magnification x 40 with 7000 ms-acquisition using ZEN imaging software (Zen 2.0 blue version, Zeiss) at the Imagopole platform (Institut Pasteur).

### Protein microarray binding analyses {#sec4.4.10}

All experiments were performed at 4°C using ProtoArray Human Protein Microarrays (Thermo Fisher Scientific). Microarrays equilibrated at 4°C for 15 min were then blocked for 1h in blocking solution (50 mM HEPES pH 7.5, 200 mM NaCl, 0.08% Triton X-100, 20 mM reduced glutathione, 1 mM DTT, 25% glycerol, 1 X synthetic block; Thermo Fisher) under gentle shaking (50 rpm). After 5 washes in 0.1% Tween 20-PBS (5 min each) and once in synthetic block, protein arrays were incubated for 1h30 with IgG antibodies at 2.5 μg/ml in 0.1% Tween 20-PBS (under 50 rpm shaking). After washings (as above), arrays were incubated for 1h30 with Alexa Fluor 647-conjugated goat-anti human IgG (at 1 μg/ml in PBS; Thermo Fisher Scientific). After washings (as above), arrays were soaked in deionized water and dried by centrifugation at 200 x g for 1 min. Fluorescence on microarrays was detected using GenePix 4000B microarray scanner (Molecular Devices) and GenePix Pro 6.0 software (Molecular Devices) with 100% laser power, PMT 400V and a spot resolution of 10 μm. Fluorescence intensities were quantified using Spotxel® software (SICASYS Software GmbH, Germany). Mean fluorescence intensity (MFI) signals for each antibody (from duplicate protein spots) was plotted against the reference antibody mGO53 (isotype, non-HIV-1, non polyreactive control) using GraphPad Prism software (v6.0a, GraphPad Prism Inc.). For each antibody, Z-scores were calculated using ProtoArray® Prospector software (v5.2.3, Thermo Fisher Scientific), and were plotted against mGO53 antibody control as reference. Deviation (σ) to the diagonal line y = x, and polyreactivity index (PI) values were calculated as previously described ([@bib35]). The PI corresponds to the Gaussian mean of protein MFI distances from the y = x line plotted in GraphPad Prism software (v6.0a, GraphPad Prism Inc.). Antibodies were defined as polyreactive when PI \> 0.21 ([@bib35]). The crossreactivity testing for the 4 mucosal HIV-1 antibodies were performed in 2 independent experiments. Sequence alignments based on the structural superposition between gp41^HR2^ cluster II peptite (from PDB ID: [1ENV](pdb:1ENV){#intref0055}) and MAPK14 (PDB ID: [5ETI](pdb:5ETI){#intref0060}) were performed using the MatchMaker command of the UCSF Chimera software (v1.9; \[[@bib42]\]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

The numbers of V~H~, Vκ and Vλ mutations were compared across groups of antibodies using unpaired Student's t test with Welch's correction. Percentages of transcytosis and levels of infectivity were compared for each antibody to mGO53 negative control group using Mann-Whitney test. Bivariate correlations were assayed using two-tailed Pearson correlation test. Statistical analyses were performed using GraphPad Prism software (v6.0a, GraphPad Prism Inc.).

Supplemental Information {#app2}
========================

Document S1. Figures S1--S7Table S1. Clinical Characteristics of HIV-1-Infected Donors, Related to STAR MethodsTable S2. Immunoglobulin Gene Repertoire and Reactivity of Intestinal IgA^+^ and IgG^+^ B Cell Antibodies from HIV-1-Infected Donors, Related to Figures 1, 2, and S2Document S2. Article plus Supplemental Information

We are grateful to all HIV-infected participants who consented to be part of this study. We thank Dr. Yoann Madec (Emerging Diseases Epidemiology Unit, Institut Pasteur) for his help with the statistical analyses, Nathalie Jolly from the clinical core of the Center for Translational Sciences (CTS, Institut Pasteur) for her assistance on the preparation of the BHUANTIVIH protocol, Sandrine Schmutz and Sophie Novault for their help with single-cell sorting (CTS, Institut Pasteur), and Dr. Jagadeesh Bayry (Centre de Recherche des Cordeliers, Paris) for manuscript editing. We also thank the NIH AIDS Reagent Program (division of AIDS, NIAID, NIH) for contributing reagents and the Agence National de Recherche sur le SIDA et les hépatites virales (ANRS) for an equipment grant. Work in the O.S. lab is funded by the Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR-10-LABX-77), the Labex IBEID (ANR-10-IHUB-0002), the "TIMTAMDEN" ANR-14-CE14-0029, the "CHIKV-Viro-Immuno" ANR-14-CE14-0015-01, and the Gilead HIV Cure program. H.M. received core grants from the G5 Institut Pasteur program, the Milieu Intérieur program (ANR-10-LABX-69-01), and INSERM. This work was funded by the European Research Council (ERC)-Seventh Framework Program (ERC-2013-StG 337146). C.P., A.K., and T.H. were supported by the ERC-2013-StG 337146 program and J.P. by an ANRS postdoctoral fellowship. J.D.D. was supported by an ERC starting grant (ERC-2015-StG 678905).

Author Contributions {#sec5}
====================

H.M. conceived the study and designed experiments. T.P., L.L., and L.H. provided biological human samples. C.P., A. Kök, C.P., A. Kanyavuz, V.L., T.B., F.G.-B., J.P., T.H., O.S., J.D.D., L.H., and H.M. performed and analyzed the experiments. T.R. and H.W. provided the collection of expression vectors for mucosal IgG antibodies. C.P. and H.M. wrote the manuscript with contributions from all the authors.

Declaration of Interests {#sec6}
========================

The authors declare no competing interests.

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2019.03.032>.

[^1]: These authors contributed equally

[^2]: These authors contributed equally

[^3]: Lead Contact
